Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patients

被引:1
作者
Meyer, Claus [1 ]
Stadt, Udo Zur [2 ]
Escherich, Gabriele [3 ]
Hofmann, Julia [1 ]
Binato, Renata [4 ]
Barbosa, Thayana da Conceicao [5 ]
Emerenciano, Mariana [5 ]
Pombo-de-Oliveira, Maria S. [5 ]
Horstmann, Martin [6 ,7 ]
Marschalek, Rolf [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Biol ZAFES, D-60438 Frankfurt, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Hamburg, Germany
[3] Clin Pediat Hematol Oncol, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[4] Inst Nacl Canc, Bone Marrow Transplantat Unit, Rio De Janeiro, RJ, Brazil
[5] Inst Nacl Canc, Res Ctr, Pediat Hematol Oncol Program, Rio De Janeiro, RJ, Brazil
[6] Univ Hamburg, Childhood Canc Res Inst, Hamburg, Germany
[7] Univ Hamburg, Clin Pediat Hematol & Oncol, UKE, Hamburg, Germany
来源
AMERICAN JOURNAL OF BLOOD RESEARCH | 2013年 / 3卷 / 02期
关键词
Childhood leukemia; cancer genetics; gene deletion; IKAROS; IKZF1; leukemia markers;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chromosomal translocations resulting in chimeric fusion genes are prototypic for pediatric leukemia patients. The most known fusions are ETV6-RUNX1 or BCR-ABL1 in B-cell progenitor ( BCP)-ALL, and rearrangements of MLL in pediatric ALL and AML. Genome-wide sequencing projects have revealed additional, recurrent gene mutations in B cell malignancies. One of these mutations comprises the IKZF1 gene, encoding the IKAROS transcription factor which is one of the essential transcription factors driving lymphoid development. IKZF1 deletions were first identified by SNP arrays in ALL patients, and later identified with a high prevalence in BCR-ABL1(+) patients. IKZF1 deletions turned out to be an independent prognostic marker associated with a poor outcome. Here, we characterized IKZF1 deletions in pediatric BCP-ALL patients by combining MLPA mapping experiments with long distance inverse PCR. The aim of our study was also to compare existing methods with our approach. Our attempt confirmed many of the existing data but revealed a more complex pattern of recombination sites, including a total of 4 recombination hotspots. This extended knowledge was translated into a novel, multiplex PCR assay that allows to perform IKZF1 deletion analyses by using a 2-tube PCR approach.
引用
收藏
页码:165 / +
页数:28
相关论文
共 21 条
[1]   Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia [J].
Caye, Aurelie ;
Beldjord, Kheira ;
Mass-Malo, Kelly ;
Drunat, Severine ;
Soulier, Jean ;
Gandemer, Virginie ;
Baruchel, Andre ;
Bertrand, Yves ;
Cave, Helene ;
Clappier, Emmanuelle .
HAEMATOLOGICA, 2013, 98 (04) :597-601
[2]   Ikaros transcription factors: flying between stress and inflammation [J].
Chrousos, GP ;
Kino, T .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :844-848
[3]   A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study [J].
Den Boer, Monique L. ;
van Slegtenhorst, Marjon ;
De Menezes, Renee X. ;
Cheok, Meyling H. ;
Buijs-Gladdines, Jessica G. C. A. M. ;
Peters, Susan T. C. J. M. ;
Van Zutven, Laura C. M. ;
Beverloo, H. Berna ;
Van der Spek, Peter J. ;
Escherich, Gaby ;
Horstmann, Martin A. ;
Janka-Schoub, Gritta E. ;
Kamps, Willem A. ;
Evans, William E. ;
Pieters, Rob .
LANCET ONCOLOGY, 2009, 10 (02) :125-134
[4]   THE IKAROS GENE IS REQUIRED FOR THE DEVELOPMENT OF ALL LYMPHOID LINEAGES [J].
GEORGOPOULOS, K ;
BIGBY, M ;
WANG, JH ;
MOLNAR, A ;
WU, P ;
WINANDY, S ;
SHARPE, A .
CELL, 1994, 79 (01) :143-156
[5]   IKAROS, AN EARLY LYMPHOID-SPECIFIC TRANSCRIPTION FACTOR AND A PUTATIVE MEDIATOR FOR T-CELL COMMITMENT [J].
GEORGOPOULOS, K ;
MOORE, DD ;
DERFLER, B .
SCIENCE, 1992, 258 (5083) :808-812
[6]   Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMAALWP) [J].
Iacobucci, Ilaria ;
Storlazzi, Clelia Tiziana ;
Cilloni, Daniela ;
Lonetti, Annalisa ;
Ottaviani, Emanuela ;
Soverini, Simona ;
Astolfi, Annalisa ;
Chiaretti, Sabina ;
Vitale, Antonella ;
Messa, Francesca ;
Impera, Luciana ;
Baldazzi, Carmen ;
D'Addabbo, Pietro ;
Papayannidis, Cristina ;
Lonoce, Angelo ;
Colarossi, Sabrina ;
Vignetti, Marco ;
Piccaluga, Pier Paolo ;
Paolini, Stefania ;
Russo, Domenico ;
Pane, Fabrizio ;
Saglio, Giuseppe ;
Baccarani, Michele ;
Foa, Robin ;
Martinelli, Giovanni .
BLOOD, 2009, 114 (10) :2159-2167
[7]   Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes [J].
Klug, CA ;
Morrison, SJ ;
Masek, M ;
Hahm, K ;
Smale, ST ;
Weissman, IL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :657-662
[8]   High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression [J].
Kuiper, R. P. ;
Schoenmakers, E. F. P. M. ;
van Reijmersdal, S. V. ;
Hehir-Kwa, J. Y. ;
van Kessel, A. Geurts ;
van Leeuwen, F. N. ;
Hoogerbrugge, P. M. .
LEUKEMIA, 2007, 21 (06) :1258-1266
[9]   Upstream of ikaros [J].
Liberg, D ;
Smale, ST ;
Merkenschlager, M .
TRENDS IN IMMUNOLOGY, 2003, 24 (11) :567-570
[10]   IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report [J].
Martinelli, Giovanni ;
Iacobucci, Ilaria ;
Storlazzi, Clelia Tiziana ;
Vignetti, Marco ;
Paoloni, Francesca ;
Cilloni, Daniela ;
Soverini, Simona ;
Vitale, Antonella ;
Chiaretti, Sabina ;
Cimino, Giuseppe ;
Papayannidis, Cristina ;
Paolini, Stefania ;
Elia, Loredana ;
Fazi, Paola ;
Meloni, Giovanna ;
Amadori, Sergio ;
Saglio, Giuseppe ;
Pane, Fabrizio ;
Baccarani, Michele ;
Foa, Robin .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5202-5207